These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 21421459)

  • 1. Direct antitumour activity of zoledronic acid: preclinical and clinical data.
    Bosch-Barrera J; Merajver SD; Menéndez JA; Van Poznak C
    Clin Transl Oncol; 2011 Mar; 13(3):148-55. PubMed ID: 21421459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A.
    Cirak Y; Varol U; Atmaca H; Kisim A; Sezgin C; Karabulut B; Uzunoglu S; Uslu R; Karaca B
    BJU Int; 2012 Dec; 110(11 Pt C):E1147-54. PubMed ID: 22882676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zoledronic acid inhibits pulmonary metastasis dissemination in a preclinical model of Ewing's sarcoma via inhibition of cell migration.
    Odri G; Kim PP; Lamoureux F; Charrier C; Battaglia S; Amiaud J; Heymann D; Gouin F; Redini F
    BMC Cancer; 2014 Mar; 14():169. PubMed ID: 24612486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extracellular Ca(2+)-dependent enhancement of cytocidal potency of zoledronic acid in human oral cancer cells.
    Inoue S; Arai N; Tomihara K; Takashina M; Hattori Y; Noguchi M
    Eur J Pharmacol; 2015 Aug; 761():44-54. PubMed ID: 25934567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zoledronic acid at subtoxic dose extends osteoblastic stage span of primary human osteoblasts.
    Zara S; De Colli M; di Giacomo V; Zizzari VL; Di Nisio C; Di Tore U; Salini V; Gallorini M; Tetè S; Cataldi A
    Clin Oral Investig; 2015 Apr; 19(3):601-11. PubMed ID: 25055744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma.
    Veltman JD; Lambers ME; van Nimwegen M; Hendriks RW; Hoogsteden HC; Hegmans JP; Aerts JG
    Br J Cancer; 2010 Aug; 103(5):629-41. PubMed ID: 20664588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction.
    Neville-Webbe HL; Coleman RE; Holen I
    Br J Cancer; 2010 Mar; 102(6):1010-7. PubMed ID: 20160726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties.
    Pozzi S; Vallet S; Mukherjee S; Cirstea D; Vaghela N; Santo L; Rosen E; Ikeda H; Okawa Y; Kiziltepe T; Schoonmaker J; Xie W; Hideshima T; Weller E; Bouxsein ML; Munshi NC; Anderson KC; Raje N
    Clin Cancer Res; 2009 Sep; 15(18):5829-39. PubMed ID: 19737962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticancer properties of zoledronic acid.
    Green J; Lipton A
    Cancer Invest; 2010 Nov; 28(9):944-57. PubMed ID: 20879838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zoledronic acid effectiveness against breast cancer metastases - a role for estrogen in the microenvironment?
    Steinman RA; Brufsky AM; Oesterreich S
    Breast Cancer Res; 2012 Sep; 14(5):213. PubMed ID: 23014660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The in vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer.
    Morgan C; Lewis PD; Jones RM; Bertelli G; Thomas GA; Leonard RC
    Acta Oncol; 2007; 46(5):669-77. PubMed ID: 17562444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisphosphonates in lung cancer: can they provide benefits beyond prevention of skeletal morbidity?
    Hirsh V
    Anticancer Agents Med Chem; 2012 Feb; 12(2):137-43. PubMed ID: 21864233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis.
    Daubiné F; Le Gall C; Gasser J; Green J; Clézardin P
    J Natl Cancer Inst; 2007 Feb; 99(4):322-30. PubMed ID: 17312309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cutting the limits of aminobisphosphonates: new strategies for the potentiation of their anti-tumour effects.
    Marra M; Abbruzzese A; Addeo R; Del Prete S; Tassone P; Tonini G; Tagliaferri P; Santini D; Caraglia M
    Curr Cancer Drug Targets; 2009 Nov; 9(7):791-800. PubMed ID: 20025567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Doses effects of zoledronic acid on mineral apatite and collagen quality of newly-formed bone in the rat's calvaria defect.
    Olejnik C; Falgayrac G; During A; Cortet B; Penel G
    Bone; 2016 Aug; 89():32-39. PubMed ID: 27168397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature.
    Gnant M; Clézardin P
    Cancer Treat Rev; 2012 Aug; 38(5):407-15. PubMed ID: 21983264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms.
    Quinn JE; Brown LG; Zhang J; Keller ET; Vessella RL; Corey E
    Prostate Cancer Prostatic Dis; 2005; 8(3):253-9. PubMed ID: 15999121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of zoledronic acid in an L6-L7 rabbit spine fusion model.
    Bransford R; Goergens E; Briody J; Amanat N; Cree A; Little D
    Eur Spine J; 2007 Apr; 16(4):557-62. PubMed ID: 16967298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bolus or weekly zoledronic acid administration does not delay endochondral fracture repair but weekly dosing enhances delays in hard callus remodeling.
    McDonald MM; Dulai S; Godfrey C; Amanat N; Sztynda T; Little DG
    Bone; 2008 Oct; 43(4):653-62. PubMed ID: 18582604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic suppression of human breast cancer cells by combination of plumbagin and zoledronic acid In vitro.
    Qiao H; Wang TY; Yan W; Qin A; Fan QM; Han XG; Wang YG; Tang TT
    Acta Pharmacol Sin; 2015 Sep; 36(9):1085-98. PubMed ID: 26235741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.